1. Bioequivalence study of dacomitinib and Vizimpro® in healthy Chinese volunteers under fasting and fed conditions: A randomized, open‐label, single‐dose, crossover trial.
- Author
-
Yang, Xiaojia, Li, Jinfang, Zhang, Taihui, Xia, Qinping, Zhang, Wei, Cui, Yike, and He, Wen
- Subjects
- *
CROSSOVER trials , *GENERIC drug manufacturing , *FASTING , *DRUG approval , *VOLUNTEERS , *VOLUNTEER service - Abstract
This study aimed to evaluate the bioequivalence between test tablet dacomitinib and reference product Vizimpro® under fasting and fed conditions and assess their pharmacokinetic (PK) and safety profiles for gaining marketing approval of the new generic drug. A single‐center, randomized, open‐label, single‐dose, two‐treatment, two‐period, crossover bioequivalence study was conducted in healthy Chinese subjects. Eligible healthy subjects randomly received a single 45 mg dose of test or reference formulations with an administration sequence of test tablet (T), reference tablet (R), or (RT), under both fasting and fed conditions, and each single administration was followed by a 21‐day washout period. Plasma concentrations and corresponding non‐compartmental PK parameters of dacomitinib were determined. The 90% confidence intervals of the geometric mean ratio (GMR) (test/reference) for Cmax, AUC0–t, and AUC0–∞, respectively, were 97.75%–119.99%, 101.00%–115.09%, and 100.27%–113.90% under fasting conditions and 95.20%–104.94%, 97.24%–102.23%, and 97.27%–101.88% under fed conditions, which were within the limits of 80%–125%. Under fasting and fed conditions, the PK characteristics of the test dacomitinib tablet and reference Vizimpro® were comparable; the two formulations of dacomitinib were demonstrated to be bioequivalent and well‐tolerated in healthy Chinese volunteers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF